Cargando…

Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice

Increasing evidence suggests that mucosally targeted vaccines will enhance local humoral and cellular responses whilst still eliciting systemic immunity. We therefore investigated the capacity of nasal, sublingual or vaginal delivery of DNA-PEI polyplexes to prime immune responses prior to mucosal p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mann, Jamie F. S., McKay, Paul F., Arokiasamy, Samantha, Patel, Reeyeshkumar K., Tregoning, John S., Shattock, Robin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691144/ https://www.ncbi.nlm.nih.gov/pubmed/23826293 http://dx.doi.org/10.1371/journal.pone.0067412

Ejemplares similares

Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection()
por: Mann, Jamie F.S., et al.
Publicado: (2013)

Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice
por: Van Roey, Griet A, et al.
Publicado: (2012)

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen()
por: Mann, J.F.S., et al.
Publicado: (2012)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations
por: Pattani, Aditya, et al.
Publicado: (2012)

Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2017)

P11-09. Mucosal vaccination with a transferrin-gp140 conjugate via the nasal but not vaginal route elicits robust systemic and vaginal IgG and IgA responses
por: Mann, JF, et al.
Publicado: (2009)

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation
por: Mann, JF, et al.
Publicado: (2012)

Corrigendum: Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2018)

A “Prime-Pull” Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice
por: Tregoning, John S., et al.
Publicado: (2013)

Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms
por: Donnelly, Louise, et al.
Publicado: (2011)

Blocking T‐cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity
por: Mann, Jamie F. S., et al.
Publicado: (2021)

Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen
por: Arias, Mauricio A., et al.
Publicado: (2011)

P11-06. Intravaginal administration of HIV-1ZM96 gp140 augments systemic and mucosal antibody responses following systemic priming with adjuvanted protein
por: Cranage, M, et al.
Publicado: (2009)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
por: McKay, PF, et al.
Publicado: (2012)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses
por: Curran, Rhonda M., et al.
Publicado: (2009)

Poly(2-oxazoline)/saRNA Polyplexes for Targeted and Nonviral Gene Delivery
por: Hayes, Graham, et al.
Publicado: (2023)

A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
por: Kratochvil, Sven, et al.
Publicado: (2017)

Antibody responses after intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation
por: Cranage, Martin P., et al.
Publicado: (2011)

Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses
por: McKay, Paul F., et al.
Publicado: (2017)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study
por: Cosgrove, Catherine A., et al.
Publicado: (2016)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes
por: Joseph, Sarah, et al.
Publicado: (2017)

Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses
por: McKay, PF, et al.
Publicado: (2012)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
por: Lewis, DJ, et al.
Publicado: (2009)

Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice
por: King, Deborah F. L., et al.
Publicado: (2015)

P11-12. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140
por: Morrow, RJ, et al.
Publicado: (2009)

TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes
por: McKay, Paul F., et al.
Publicado: (2016)

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140
por: Donnelly, L, et al.
Publicado: (2009)

Effect of Plasmid DNA Size on Chitosan or Polyethyleneimine Polyplexes Formulation
por: Valente, J.F.A., et al.
Publicado: (2021)

The role of intermolecular disulfide bonding in deposition of GP140 in the extracellular matrix
Publicado: (1984)

Characterization and Immunogenicity of HIV Envelope gp140 Zera(®) Tagged Antigens
por: Ximba, Phindile, et al.
Publicado: (2020)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Efficient Shielding of Polyplexes Using Heterotelechelic Polysarcosines
por: Klein, Philipp Michael, et al.
Publicado: (2018)

Effect of Polyplex Size on Penetration into Tumor Spheroids
por: Casadidio, Cristina, et al.
Publicado: (2023)

Gene Targeting to the Cerebral Cortex Following Intranasal Administration of Polyplexes
por: Petkova, Asya I., et al.
Publicado: (2022)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_45147ql20l4vs9gvlvu15nl0jv